Who are e.-coli-nissle's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimo-San vaginal gel, Estrogen + probiotics, Probiotic Supplement, Lactobacillus plantarum, INF108F probiotic, Lactobacillus casei.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/e-coli-nissle.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

e.-coli-nissle — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

e.-coli-nissle (e.-coli-nissle) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

phase 3 Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

e.-coli-nissle (e.-coli-nissle) — GWT-TUD GmbH. E. coli Nissle is a probiotic bacterium that modulates the gut microbiome to exert its therapeutic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
e.-coli-nissle TARGET	e.-coli-nissle	GWT-TUD GmbH	phase 3	Probiotic
Trimo-San vaginal gel	Trimo-San vaginal gel	The University of Texas Health Science Center, Houston	marketed	Vaginal pH regulator / Probiotic adjunct
Estrogen + probiotics	Estrogen + probiotics	University Hospital, Ghent	marketed	Combination therapy (hormone replacement + probiotic)
Probiotic Supplement	Probiotic Supplement	Sheppard Pratt Health System	marketed	Probiotic supplement
Lactobacillus plantarum	Lactobacillus plantarum	Shenzhen People's Hospital	marketed	Probiotic
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus casei	Lactobacillus casei	Hospital Cristo Re	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). e.-coli-nissle — Competitive Intelligence Brief. https://druglandscape.com/ci/e-coli-nissle. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing